EUVIMEDEUVIMED entdecken
Crossref

Dually targeted AR-PROTAC prodrug nanomedicine coordinates AR degradation in tumor cells and CD8+ T cells for enhanced prostate cancer immunotherapy

Tao Liu, Guohua Liu, Cheng Fang, Haiping Zhong, Yanliang Dong, Yi Shao, Shengju Song, Jun Wu, Shutao Guo, Zhiqun Shang

Chinese Chemical Letters · 2026-11 · 113604

DOI: 10.1016/j.cclet.2026.113604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chinese Chemical Letters, 2026-11. Verfasst von Tao Liu und 9 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Liu, T., Liu, G., Fang, C., Zhong, H., Dong, Y., Shao, Y., Song, S., Wu, J., Guo, S., & Shang, Z. (2026). Dually targeted AR-PROTAC prodrug nanomedicine coordinates AR degradation in tumor cells and CD8+ T cells for enhanced prostate cancer immunotherapy. Chinese Chemical Letters, 113604. https://doi.org/10.1016/j.cclet.2026.113604

Vancouver

Liu T, Liu G, Fang C, Zhong H, Dong Y, Shao Y, et al. Dually targeted AR-PROTAC prodrug nanomedicine coordinates AR degradation in tumor cells and CD8+ T cells for enhanced prostate cancer immunotherapy. Chinese Chemical Letters. 2026:113604. doi:10.1016/j.cclet.2026.113604

BibTeX
@article{Liu2026,
  author = {Liu, Tao and Liu, Guohua and Fang, Cheng and Zhong, Haiping and Dong, Yanliang and Shao, Yi and Song, Shengju and Wu, Jun and Guo, Shutao and Shang, Zhiqun},
  title = {Dually targeted AR-PROTAC prodrug nanomedicine coordinates AR degradation in tumor cells and CD8+ T cells for enhanced prostate cancer immunotherapy},
  journal = {Chinese Chemical Letters},
  year = {2026},
  pages = {113604},
  doi = {10.1016/j.cclet.2026.113604}
}
Kostenlos starten →